Comparison · NCT02032823-5dcad09c
Olaparib vs Placebo: Distant Disease Free Survival (DDFS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Olaparib vs Placebo: Distant Disease Free Survival (DDFS). Trial comparisons, record NCT02032823-5dcad09c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02032823-5dcad09c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0966 | 0.0792 | 0.117 | wilson | |
| Risk in group 2 | 0.166 | 0.143 | 0.192 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0695 | -0.1 | -0.0387 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.582 | 0.455 | 0.743 | log | |
| Odds ratio, group 1 over group 2 | 0.537 | 0.406 | 0.71 | log | |
| Number needed to treat, for one fewer participant with the outcome on Olaparib than on Placebo | 14.4 | 9.96 | 25.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Olaparib | Olaparib tablets 300mg taken orally twice daily. | 89 | 921 | OG000 |
| Group 2 | Placebo | Placebo tablets taken orally twice daily. | 152 | 915 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Distant Disease Free Survival (DDFS)
- Description
- A DDFS event is defined as documented evidence of first distant recurrence of breast cancer or death from any cause
- Time frame
- From date of randomisation to data cut off: 27 March 2020 (approximately 5 years 11 months)
- Population
- Full Analysis Set (FAS)
Source ClinicalTrials.gov
Trial
- Title
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
- NCT number
- NCT02032823
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- Olaparib, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2021-12-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02032823?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02032823-5dcad09c